Minireviews
Copyright ©2014 Baishideng Publishing Group Inc.
World J Clin Cases. Nov 16, 2014; 2(11): 654-660
Published online Nov 16, 2014. doi: 10.12998/wjcc.v2.i11.654
Table 4 Case series with epidemiology, management and outcomes of scrotal squamous cell carcinoma published after 2000
Ref.nDesignCohort characteristics Summary
Stern et al[17], 200217Prospective multi-institutional cohort study892 men first treated with PUVADose-dependent increase in the risk of genital tumors in men treated with PUVA
Seabra et al[19], 20076Retrospective single institutionAge: 52 (31-89) Race: Ca: 2; Bl: 2; Oth: 1; Unknown: 1 Staging: LC: 4, RL: 1, DD: 14/6 WLE; 1/6 WLE + SLNB; 1/6 was unresectable: 1 developed LN metastasis and was treated with chemo/radiation Patient with unresectable disease and was treated with chemotherapy and subsequently died
Wright et al[2], 2008151SEER (1973-2002)Age: 682 Race: Ca 117 (77.5); Bl 24 (15.9); Oth 10 (6.6)SCC had the worse survival compared to other histological subtypes
Verhoeven et al[1], 201053NCR (1989-2006)Age: 56.5 Staging: Stg 0: 1 (1.9), Stg 1: 22 (41.5), Stg 2: 18 (34), Stg 3: 2 (3.8), Stg 4: 0, Unk: 10 (18.9)SCC had the worse survival compared to other histological subtypes: 1 yr relative survival 93% 3 yr relative survival 80% 5 yr relative survival 77%
Johnson et al[16], 2013269SEER (1973-2006)Age: 65.42± 14.9 Race: Ca 206 (76.6%), Bl 43 (16.0%), As 12 (4.5%), Hi 18 (6.7%), Oth 8 (3.0%) Staging: LC 205 (76.2%), RL 54 (20.1%), DD 10 (3.7%)The median OS for patients with SCC was 115 (95%CI: 97-133) mo
Matoso et al[18], 201429Retrospective multi-institutionalAge: 55 (30-74) Race: Ca 19 (65.5%), Bl 10 (34.5%) Follow up: 37 mo25/29 WLE; 1/29 WLE + LND; 3/29 imiquimod post WLE: 13 (45%) with1 margins required re-excision1 3/29 local recurrence: 2 WLE; 1 WLE/RT 3 /29 with lymphadenopathy lost to follow-up